코어라인소프트Corelinesoft Revenue and Competitors
Estimated Revenue & Valuation
- 코어라인소프트Corelinesoft's estimated annual revenue is currently $10.6M per year.
- 코어라인소프트Corelinesoft's estimated revenue per employee is $140,000
Employee Data
- 코어라인소프트Corelinesoft has 76 Employees.
- 코어라인소프트Corelinesoft grew their employee count by 15% last year.
코어라인소프트Corelinesoft's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Business Development, North America | Reveal Email/Phone |
2 | Country Manager | Reveal Email/Phone |
3 | Clinical Application Specialist | Reveal Email/Phone |
4 | General Manager | Reveal Email/Phone |
코어라인소프트Corelinesoft Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $12.6M | 90 | -36% | $14.1M | N/A |
#2 | $83.2M | 468 | -3% | $251M | N/A |
#3 | $14M | 100 | 1% | N/A | N/A |
#4 | $14.6M | 0 | N/A | $12.5M | N/A |
#5 | $30.3M | 197 | -6% | N/A | N/A |
#6 | $0.1M | 6 | -25% | $2.6M | N/A |
#7 | $45.1M | 293 | 2% | N/A | N/A |
#8 | $4.8M | 43 | -7% | N/A | N/A |
#9 | $399.3M | 2037 | 40% | N/A | N/A |
#10 | $44M | 286 | 4% | N/A | N/A |
What Is 코어라인소프트Corelinesoft?
About Coreline soft We develop AI-based imaging diagnosis package, specializing in lungs. This includes lung cancer screening(LCS), COPD quantification, and coronary artery calcification (CAC) systems, we call it B3 systems, covering the 3 big diseases in thoracic imaging. More in-depth lung diagnosis products with analysis such as texture analysis for ILD/IPF and pneumonia detection including COVID-19 are soon to be expected.  √ The Official solution provider for the nationwide lung cancer screening program in Korea (K- LUCAS) from 2017, which is the 2nd state-level-reimbursed LCS program following the US from 2015 √ The Official solution provider of 4-ITLR project by the Nelson Team (Erasmus MC and iDNA in the Netherlands), which is a large early detection LCS Trial-based on B3 system. Two hospitals in Germany, DKFZ Heidelberg and Univ Hosp of Essen, are the members of this trial and our systems will be implemented in these hospitals from 2021. √ Imminent Official solution provider for the German Trial by multi-university hospitals which is a pilot project to prove a national support necessary for LCS in Germany. √ Our COPD systems are used by European customers such as NZ Leuven Belgium, Leicester Univ UK, Parma Univ Italy obtaining the appraisal as the best of breed for early detection, phenotyping, surgery support, and etc.
keywords:N/AN/A
Total Funding
76
Number of Employees
$10.6M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $19.1M | 76 | -8% | N/A |
#2 | $10.8M | 77 | 7% | N/A |
#3 | N/A | 79 | -32% | N/A |
#4 | $11.7M | 81 | 14% | N/A |
#5 | N/A | 82 | -5% | N/A |